Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 25, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 500,000 Ordinary shares of 25 pence each.
- Repurchase Price Range: Highest price paid was 1,177.5 pence per share; lowest price paid was 1,167.5 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.70% of total issued share capital and 9.53% of total voting rights).
- Shares in Issue: 5,173,546,173 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 500,000 repurchased shares. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share buyback transaction in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,173,546,173) for calculating disclosure thresholds under FSA rules.
- Confirm the impact of the 500,000 share cancellation on the total issued share capital.
- Note that the filing does not contain financial performance data; refer to Form 20-F for full financial statements.